A COMPARATIVE STUDY OF ORAL PSORALEN VS METHYLPREDNISOLONE WITH NARROW BAND UVB THERAPY IN VITILIGO

Objective: The efficacy and safety evaluation of oral Psoralen and of oral Methylprednisolone along with narrow-band ultraviolet B (NB-UVB). To observe the safety and efficacy of oral Psoralen in patients of Vitiligo. To observe the safety and efficacy of oral Methylprednisolone along with NB-UVB in patients of Vitiligo. To compare the safety and efficacy of oral Psoralen and oral Methylprednisolone along with NB-UVB during the study. To assess the dermatological life quality index (DLQI) in patients of Vitiligo before, during treatment, and after treatment. Methodology: A randomized controlled trial was conducted involving 76 patients diagnosed with generalized vitiligo. Patients were randomly assigned to either Group A or Group B. Group A received oral psoralen (0.3–0.6 mg/kg) followed by Twice-weekly sessions of NB-UVB therapy along with methylprednisolone. Results: As per the observations, the DLQI of the patients treated with the methylprednisolone with NB-UVB were showing better results as compared to the oral psoralen group. Conclusion: Even though vitiligo does not pose a direct threat to a person’s physical or mental health, it does cause a great deal of suffering for those who suffer from it and their loved ones. Therefore, treatment is necessary. While there are a number of systemic and topical treatments for this condition, phototherapy – and particularly NB-UVB – is among the most effective and safest options.